Greenland Mines Ltd Warrant (formerly Klotho Neurosciences) SEC Filings

Greenland Mines Ltd reports that Strategic EP, LLC and Alexander Chase Deitch collectively beneficially own 6,687,472 shares of Common Stock, representing 5.5% of the class as of 03/04/2026. The filing states the holdings reflect shared voting and shared dispositive power of 6,687,472 shares.

The Reporting Persons also hold warrants to purchase 6,687,472 shares, but exercise of those warrants is conditioned on stockholder approval and therefore those underlying shares are not treated as beneficially owned under Rule 13d-3. The reported outstanding share base is 121,238,660 shares.

Greenland Mines Ltd, formerly Klotho Neurosciences, is hosting a publicly accessible investor webcast on March 12, 2026, to present its new strategy and assets. The company recently completed the acquisition of Greenland Mines on March 4, 2026, paying consideration in convertible preferred equity subject to shareholder approval.

Following the deal, the business now operates two divisions: Natural Resources and Cell and Gene Therapy. Greenland Mines owns 80% of the Skaergaard Project in southeast Greenland, with an option on the remaining 20%. A 2022 NI 43-101 report shows 25.4 Moz PdEq and 23.5 Moz AuEq, with an estimated in-situ resource value of about $68 billion at February 2026 metal prices. A new drilling and development program aims to double the resource to roughly 50 million contained ounces of gold, palladium, and platinum.

Greenland Mines Ltd, formerly Klotho Neurosciences, is hosting a publicly accessible investor webcast on March 12, 2026, to present its new strategy and assets. The company recently completed the acquisition of Greenland Mines on March 4, 2026, paying consideration in convertible preferred equity subject to shareholder approval.

Following the deal, the business now operates two divisions: Natural Resources and Cell and Gene Therapy. Greenland Mines owns 80% of the Skaergaard Project in southeast Greenland, with an option on the remaining 20%. A 2022 NI 43-101 report shows 25.4 Moz PdEq and 23.5 Moz AuEq, with an estimated in-situ resource value of about $68 billion at February 2026 metal prices. A new drilling and development program aims to double the resource to roughly 50 million contained ounces of gold, palladium, and platinum.

Klotho Neurosciences, Inc. reported that Chief Financial Officer Jeff LeBlanc acquired 2,500,000 shares of common stock on a grant/award basis. The shares were received at a price of $0.00 per share as a grant under the company’s Equity Incentive Plan, meaning no cash purchase was involved.

Following this equity award, LeBlanc directly holds 3,420,342 common shares of Klotho Neurosciences. This filing records an increase in his equity-based compensation and ownership stake through the company’s incentive program.

Klotho Neurosciences, Inc. reported that Chief Financial Officer Jeff LeBlanc acquired 2,500,000 shares of common stock on a grant/award basis. The shares were received at a price of $0.00 per share as a grant under the company’s Equity Incentive Plan, meaning no cash purchase was involved.

Following this equity award, LeBlanc directly holds 3,420,342 common shares of Klotho Neurosciences. This filing records an increase in his equity-based compensation and ownership stake through the company’s incentive program.

Klotho Neurosciences, Inc. director El-Dada Riad Hussein reported receiving a grant of 350,000 shares of Common Stock on March 4, 2026. The shares were awarded under the company’s Equity Incentive Plan and were acquired at a stated price of $0.00 per share.

Klotho Neurosciences, Inc. director El-Dada Riad Hussein reported receiving a grant of 350,000 shares of Common Stock on March 4, 2026. The shares were awarded under the company’s Equity Incentive Plan and were acquired at a stated price of $0.00 per share.

ZENTMAN SAMUEL M reported acquisition or exercise transactions in this Form 4 filing.

Klotho Neurosciences, Inc. director Samuel M. Zentman reported receiving a grant of 350,000 shares of Common Stock on March 4, 2026. The shares were awarded at a stated price of $0.00 per share as a grant under the company’s Equity Incentive Plan.

Following this equity award, Zentman’s directly held Common Stock increased to 1,086,440 shares. This filing reflects a non-cash stock grant that further aligns the director’s ownership with the company’s performance.

ZENTMAN SAMUEL M reported acquisition or exercise transactions in this Form 4 filing.

Klotho Neurosciences, Inc. director Samuel M. Zentman reported receiving a grant of 350,000 shares of Common Stock on March 4, 2026. The shares were awarded at a stated price of $0.00 per share as a grant under the company’s Equity Incentive Plan.

Following this equity award, Zentman’s directly held Common Stock increased to 1,086,440 shares. This filing reflects a non-cash stock grant that further aligns the director’s ownership with the company’s performance.

Klotho Neurosciences, Inc. reported that director Shalom Hirschman acquired 350,000 shares of Common Stock on March 4, 2026. The shares were received as a grant under the company’s Equity Incentive Plan and carried a stated price of $0.00 per share.

Following this equity award, Hirschman’s direct ownership increased to 908,873 shares of Common Stock, according to the Form 4 disclosure.

Klotho Neurosciences, Inc. reported that director Shalom Hirschman acquired 350,000 shares of Common Stock on March 4, 2026. The shares were received as a grant under the company’s Equity Incentive Plan and carried a stated price of $0.00 per share.

Following this equity award, Hirschman’s direct ownership increased to 908,873 shares of Common Stock, according to the Form 4 disclosure.

McGarity Jon reported acquisition or exercise transactions in this Form 4 filing.

Klotho Neurosciences, Inc. director Jon McGarity reported receiving a grant of 350,000 shares of Common Stock on March 4, 2026. The shares were granted under the company’s Equity Incentive Plan and carried a reported price of $0.00 per share, indicating a non-cash equity award. Following this grant, McGarity’s directly held Common Stock increased to 411,277 shares, aligning his compensation more closely with shareholder interests through additional stock-based incentives.

McGarity Jon reported acquisition or exercise transactions in this Form 4 filing.

Klotho Neurosciences, Inc. director Jon McGarity reported receiving a grant of 350,000 shares of Common Stock on March 4, 2026. The shares were granted under the company’s Equity Incentive Plan and carried a reported price of $0.00 per share, indicating a non-cash equity award. Following this grant, McGarity’s directly held Common Stock increased to 411,277 shares, aligning his compensation more closely with shareholder interests through additional stock-based incentives.

Klotho Neurosciences, Inc. is acquiring privately held Greenland Mines Corp., which controls an 80% interest in, and an option for the remaining 20% of, the Skaergaard palladium‑gold‑platinum project in Southeast Greenland. The deal consideration is payable in convertible preferred stock, and on an as‑converted basis Greenland Mines is expected to own about 93% of fully diluted shares, with the transaction treated as a reverse merger for accounting purposes. Klotho will operate two divisions, Natural Resources and Cell and Gene Therapy, and plans to change its name and ticker to reflect the Greenland Mines focus. Skaergaard hosts an NI 43‑101 Indicated and Inferred Mineral Resource of 25.4 million ounces palladium equivalent and 23.5 million ounces gold equivalent with an illustrative gross in‑situ metal value of roughly $68 billion based on February 2026 metal prices, though no economic study has yet demonstrated project viability.

Klotho Neurosciences, Inc. is acquiring privately held Greenland Mines Corp., which controls an 80% interest in, and an option for the remaining 20% of, the Skaergaard palladium‑gold‑platinum project in Southeast Greenland. The deal consideration is payable in convertible preferred stock, and on an as‑converted basis Greenland Mines is expected to own about 93% of fully diluted shares, with the transaction treated as a reverse merger for accounting purposes. Klotho will operate two divisions, Natural Resources and Cell and Gene Therapy, and plans to change its name and ticker to reflect the Greenland Mines focus. Skaergaard hosts an NI 43‑101 Indicated and Inferred Mineral Resource of 25.4 million ounces palladium equivalent and 23.5 million ounces gold equivalent with an illustrative gross in‑situ metal value of roughly $68 billion based on February 2026 metal prices, though no economic study has yet demonstrated project viability.

Klotho Neurosciences, Inc. completed a private financing on March 2, 2026 under a Securities Purchase Agreement dated February 19, 2026. The company issued 34,551,939 shares of common stock and Warrants to purchase up to an additional 34,551,939 shares, raising aggregate gross proceeds of approximately $7,750,000.

The transaction was conducted as a private placement to accredited investors under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D, without general solicitation or advertising. The Warrants and their terms are described in an earlier filing, with a form of Warrant filed as an exhibit.

Klotho Neurosciences, Inc. completed a private financing on March 2, 2026 under a Securities Purchase Agreement dated February 19, 2026. The company issued 34,551,939 shares of common stock and Warrants to purchase up to an additional 34,551,939 shares, raising aggregate gross proceeds of approximately $7,750,000.

The transaction was conducted as a private placement to accredited investors under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D, without general solicitation or advertising. The Warrants and their terms are described in an earlier filing, with a form of Warrant filed as an exhibit.

Klotho Neurosciences, Inc. stockholders held a special meeting and approved two key proposals affecting the company’s capital structure and equity compensation. First, they approved an amendment to the company’s charter to authorize a reverse stock split of the outstanding common stock at a ratio between one-for-2 and one-for-50, with the exact ratio to be set by the Board of Directors. Second, they approved an amendment to the 2024 Equity Incentive Plan to increase the number of shares of common stock available and reserved for issuance under the plan to 10,000,000 shares, subject to specified conditions.

On the January 15, 2025 record date, 73,536,722 common shares were issued and outstanding, and holders of 30,457,004 shares were present or represented by proxy, constituting a quorum. The reverse stock split proposal received 27,637,476 votes for, 2,642,876 against, and 176,650 abstentions. The equity incentive plan amendment received 11,082,522 votes for, 3,609,008 against, and 45,960 abstentions, with 15,719,514 broker non-votes.

Klotho Neurosciences, Inc. stockholders held a special meeting and approved two key proposals affecting the company’s capital structure and equity compensation. First, they approved an amendment to the company’s charter to authorize a reverse stock split of the outstanding common stock at a ratio between one-for-2 and one-for-50, with the exact ratio to be set by the Board of Directors. Second, they approved an amendment to the 2024 Equity Incentive Plan to increase the number of shares of common stock available and reserved for issuance under the plan to 10,000,000 shares, subject to specified conditions.

On the January 15, 2025 record date, 73,536,722 common shares were issued and outstanding, and holders of 30,457,004 shares were present or represented by proxy, constituting a quorum. The reverse stock split proposal received 27,637,476 votes for, 2,642,876 against, and 176,650 abstentions. The equity incentive plan amendment received 11,082,522 votes for, 3,609,008 against, and 45,960 abstentions, with 15,719,514 broker non-votes.